BiotechTube

Subcutaneous Teriparatide + Transdermal Teriparatide

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis

Conditions

Osteoporosis

Trial Timeline

Nov 1, 2009 → Sep 1, 2011

NCT ID
NCT01011556

About Subcutaneous Teriparatide + Transdermal Teriparatide

Subcutaneous Teriparatide + Transdermal Teriparatide is a phase 2 stage product being developed by Eli Lilly for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01011556. Target conditions include Osteoporosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01011556Phase 2Completed

Competing Products

20 competing products in Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
77
TeriparatideEli LillyPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
raloxifene + placeboEli LillyApproved
85
Teriparatide + Salmon CalcitoninEli LillyPhase 3
77
ForteoEli LillyPre-clinical
23
arzoxifene + PlaceboEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
77
YM529 / ONO-5920Astellas PharmaPhase 2/3
65
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77
ONO-5920 / YM529Astellas PharmaPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85